NCT02081599View on ClinicalTrials.gov

Efficacy and Safety Study of Teneligliptin (MP-513) in Combination With Insulin in Patients With Type 2 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Teneli (Teneligliptin)

DRUG

Placebo

DRUG

Insulin

Trial Locations (1)

Unknown

Investigational site, Chuo-ku

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY